Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Vicente Palomar Abril


Annals of Oncology (2019) 30 (suppl_5): v591-v601. 10.1093/annonc/mdz259


V. Palomar Abril1, T. Soria-Comes1, M. Martin Ureste2, I. Maestu Maiques1

Author affiliations

  • 1 Medical Oncology, Hospital Dr. Peset Aleixandre, 46017 - Valencia/ES
  • 2 Medical Oncology, Hospital Universitario Doctor Peset, 46017 - Valencia/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1550


There is scarce data of the impact of inflammatory indexes in locally advanced NSCLC, which is a highly heterogeneous illness. Choice of therapy is complex and often, combined CRT, either concurrently or sequentially is used. We aim to determine the impact of NLR monitoring in patients with stage III NSCLC treated with CRT.


Patients with stage III NSCLC treated with CRT were identified from Jan2010 to Dec2015 in our centre. NLR (neutrophils/lymphocytes) was retrospectively collected at baseline (B) and 5-6 weeks after CRT (C). It was considered a continuous variable and categorised (low <4, high ≥4). NLR monitoring (B and C) stratified 2 groups: good (NLR remained <4 and NLR decreased ≥4 to < 4) and poor (NLR increased <4 to ≥ 4 and NLR remained ≥4). Progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier method and log-rank test. Cox regression model was used for the multivariate analysis.


92 patients were included; median age 65.5 years (39-83); 85.87% were male and 90.3% had ECOG 0-1. Predominant histologies: adenocarcinoma (41.3%) and squamous-cell carcinoma (56.5%). Concurrent treatment in 78.9% patients and sequential in 21.1%. Median PFS and OS were 16.23 and 30.36 months (mo), in the overall population. On the multivariate analysis, the good prognostic group had significant longer median PFS and OS than the poor group: 33.9 vs 11.1 mo (p<.001) and 48.8 vs 17.4 mo (p<.001), respectively. Higher post-treatment NLR was also associated with shorter PFS and OS.Table:


Multivariate analysis
HR (95% CI)p valueHR (95% CI)p value
ECOG1.65 (0.81 – 3.38)0.1692.55 (1.17 – 5.56)0.018
Sequiential vs. Concurrent CRT0.87 (0.41 – 1.81)0.7030.87 (0.38 – 1.97)0.732
Baseline NLR1.01 (0.83 – 1.23)0.9180.84 (0.66 – 1.07)0.158
Post CRT NLR (low vs high)1.08 (1.01 – 1.15)0.0181.11 (1.05 – 1.19)<0.001
Prognostic groups (good vs poor)3.00 (1.49 – 6.02)0.0022.83 (1.30 – 6.14)0.009


NLR could be used as a prognostic factor in stage III NSCLC especially when considering its dynamic evolution. Our results provide the opportunity to evaluate this inexpensive and reproducible index as a prognostic or predictive biomarker in prospective studies, particularly with the novel use of anti-PD-1/L1 after CRT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hospital Universitario Doctor Peset.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.